Compare Davita Inc (DVA) vs Enphase Energy Inc (ENPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Enphase Energy Inc — how do they compare? Davita Inc trades at $232 (market cap $14.92B), while Enphase Energy Inc trades at $45.01 (market cap $5.93B). The key difference: Davita Inc is far larger — about 2.5× Enphase Energy Inc's market cap, and Davita Inc is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals.
| DVA | ENPH | |
|---|---|---|
Market Cap | $14.92B | $5.93B |
Sector | Health | Technology |
52-Week High | $235.71 | $72.33 |
52-Week Low | $103.87 | $26.12 |
Enterprise Value | $27.47B | $5.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Enphase Energy (ENPH) trades at $43.06, down 3.95% on the day, near its consensus price target of $42.79. The stock shows a bearish technical signal with declining cash flows and mixed earnings trends, though recent quarters have beaten estimates. Recent news includes product expansions in Australia and New Zealand and involvement in AI data center power standards, providing some positive catalysts amid overall market caution.
Outlook remains cautious with high valuation ratios (P/E 44.39) pressuring upside, while analyst sentiment is divided (40% Buy, 51% Hold). Key risks include competitive pressures and volatile solar demand, but institutional interest and strategic initiatives offer potential for recovery if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →
